ReviewEndocrine2013
Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.
Review in Endocrine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door.Heart failure reviews · 2022Review
- Review
- Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm.Journal of cachexia, sarcopenia and muscle · 2015Article
- Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines.Journal of cachexia, sarcopenia and muscle · 2015Article
- GH and the cardiovascular system: an update on a topic at heart.Endocrine · 2015Review
- Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Sarcopenic obesity in aging population: current status and future directions for research.Endocrine · 2014Review
- Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status.Endocrine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well documented in the current literature that chronic heart failure is often associated with cachexia, defined as involuntary weight loss of 5 % in 12 month or less. Clinical studies unraveled that the presence of cachexia decreases significantly mean survival of the patient. At the molecular level mainly myofibrillar proteins are degraded, although a reduced protein synthesis may also contribute to the loss of muscle mass. Endocrine factors clearly regulate muscle mass and function by influencing the normally precisely controlled balance between protein breakdown and protein synthesis The aim of the present article is to review the knowledge in the field with respect to the role of endocrine factors for the regulation of cachexia in patients with CHF and deduce treatment perspectives.
Indexed as
Identifiers
22903414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.